Valuation: NovoCure Limited

Market Cap 2B 1.75B 1.62B 1.49B 2.84B 191B 2.88B 19.35B 7.58B 93.87B 7.52B 7.36B 325B P/E 2026 *
-10.8x
P/E 2027 * -14.5x
Enterprise Value 1.78B 1.56B 1.44B 1.33B 2.52B 170B 2.56B 17.2B 6.74B 83.46B 6.68B 6.54B 289B EV / Sales 2026 *
2.53x
EV / Sales 2027 * 2.59x
Free-Float
89.99%
Yield 2026 *
-
Yield 2027 * -
1 day-6.22%
1 week-6.41%
Current month+7.00%
1 month-2.64%
3 months+53.21%
6 months+14.32%
Current year+25.37%
1 week 16.01
Extreme 16.01
18.08
1 month 13.43
Extreme 13.43
18.35
Current year 9.82
Extreme 9.82
18.92
1 year 9.82
Extreme 9.82
18.92
3 years 9.82
Extreme 9.82
42.02
5 years 9.82
Extreme 9.82
195.78
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 01/12/2025
Director of Finance/CFO 52 01/01/2025
Chief Tech/Sci/R&D Officer - 17/01/2023
Director TitleAgeSince
Director/Board Member 59 01/01/2012
Chairman 63 01/01/2009
Director/Board Member 64 05/08/2011
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

268 0.0002%
06-30Free

Head of Human Resources

1,905 0.0016%
06-30Free

Chief Executive Officer

1,905 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
-6.22%-6.41%-12.19%-61.34% 2B
-0.08%-0.12%+30.33%-2.88% 12.51B
-2.70%-5.50%+56.06%+31.24% 6B
+1.77%-0.72%+6.99%+13.93% 5.73B
-0.80%-1.93% - - 4.23B
+3.82%+5.08%-30.34%+15.21% 4.1B
+1.84%-0.61%-25.08%-26.66% 3.75B
+2.64%+3.12%+20.44%+266.67% 1.89B
-0.98%+1.78%+56.43%-5.02% 1.57B
+2.41%+0.73%-15.25%-45.68% 1.26B
Average +0.15%+0.04%+9.71%+20.61% 4.3B
Weighted average by Cap. +0.14%-0.35%+15.99%+13.12%

Financials

2026 *2027 *
Net sales 704M 616M 568M 525M 997M 67.19B 1.01B 6.8B 2.67B 32.99B 2.64B 2.59B 114B 774M 677M 624M 578M 1.1B 73.88B 1.11B 7.48B 2.93B 36.28B 2.91B 2.84B 126B
Net income -183M -160M -148M -137M -260M -17.5B -264M -1.77B -694M -8.59B -688M -673M -29.76B -136M -119M -110M -101M -193M -12.98B -196M -1.31B -515M -6.37B -510M -499M -22.07B
Net Debt -222M -194M -179M -166M -315M -21.19B -320M -2.14B -841M -10.41B -833M -815M -36.04B -
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
10/07/26 $16.25 -6.04% 303,137
09/07/26 $17.29 -0.46% 1,049,957
08/07/26 $17.37 -1.98% 3,335,527
07/07/26 $17.72 +2.31% 1,057,795
06/07/26 $17.32 +0.70% 1,711,142
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
17.29USD
Average target price
26.00USD
Spread / Average Target
+50.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock